Pay in 4 interest-free payments of $6.03 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Rising awareness among healthcare professionals regarding the long-term benefits of GLP-1 receptor agonists for weight reduction and cardiovascular health is contributing to market growth
The aim of the present review is to examine the cellular processes underlying the actions of these new, highly significant classes of peptide receptor agonists
Patients lost an average of 20.2% of their body weight on tirzepatide versus 13.7% on semaglutide after 72 weeks (Source: SURMOUNT-5 Trial, Wharton et al., NEJM 2025)
She is skilled in market estimation, forecasting, competitive benchmarking, and both primary & secondary research, enabling her to turn complex data into decision-ready insights
Key takeaway: When the daily routine is followed correctly, the tablet's results are broadly comparable to the injection
US$ 28.73
US$ 22.89
US$ 26.08
US$ 29.88
US$ 24.55
US$ 29.26
US$ 26.45
